Changes in interferon-gamma (IFN-γ) and IL-18 levels and cellular immunity were also assessed.<h4>Conclusion</h4>This study highlights the importance of gut microbiota in modulating immune responses in patients with CLD and demonstrates the effectiveness of long-term gut-modulating therapies in reducing inflammatory markers. This evidence concerns the gene IL18 and congenital secretory chloride diarrhea 1.